金龙蛤蚧平喘胶囊治疗稳定期慢性阻塞性肺疾病临床观察

目的 观察金龙蛤蚧平喘胶囊治疗稳定期慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）的疗效。方法 将58例COPD患者随机分为治疗组和对照组，每组28例。在常规治疗基础上，分别给予金龙蛤蚧平喘胶囊与安慰剂。治疗前、治疗6个月后和治疗12个月后，分别观察两组患者的肺功能、骨密度（bone mineral density，BMD）、BODE指数、COPD评估测试（COPD assessment test，CAT）问卷评分及1年内急性加重次数。结果 治疗6个月后及治疗12个月后，两组肺功能各项参数比较，差异均无统计学意义（P＞0.05）。 治疗12个月后，治疗组股骨颈BMD较治疗前显著升高（P＜0.05），而对照组股骨颈BMD较治疗前显著下降（P＜0.05）。治疗6个月后和治疗12个月后，两组BODE指数及其因子6 min步行距离积分比较，差异均有统计学意义（P＜0.05）。两组1年内急性加重次数相比，差异具有统计学意义（P＜0.05）。结论 金龙蛤蚧平喘胶囊可有效改善稳定期COPD患者的肺功能、BODE指数及生活质量，减少患者1年内急性加重次数。

Clinical Efficacy of Jinlong Gejie Pingchuan Capsule in Treatment of Stable-stage Chronic Obstructive Pulmonary Disease

Objective To investigate the clinical efficacy of Jinlong Gejie Pingchuan Capsule (for relieving asthma) in the treatment of stable-stage chronic obstructive pulmonary disease (COPD). Methods A total of 56 COPD patients were randomly divided into treatment group and control group, with 28 patients in each group. The two groups were given Jinlong Gejie Pingchuan Capsule and placebo, respectively, in addition to conventional treatment. The pulmonary function parameters, bone mineral density (BMD), body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index, score of COPD assessment test (CAT) questionnaire, and number of episodes of acute exacerbation within 1 year were observed before treatment and at 6 and 12 months after treatment. Results The pulmonary function parameters showed no significant differences between the two groups at 6 and 12 months after treatment (P>0.05). At 12 months after treatment, the treatment group showed a significant increase in BMD of the femoral neck (P<0.05), while the control group showed a significant reduction in BMD of the femoral neck (P<0.05). At 6 and 12 months after treatment, BODE index and the score on its subscale of six-minute walk distance showed significant differences between the two groups (P<0.05). The number of episodes of acute exacerbation within 1 year also showed a significant difference between the two groups (P<0.05). Conclusion In the patients with stable-stage COPD, Jinlong Gejie Pingchuan Capsule can effectively improve the pulmonary function, BODE index, and quality of life, and reduce the episodes of acute exacerbation within 1 year.